Atara Biotherapeutics (ATRA) plans to cut around 50% of its workforce, just a little over a week after the FDA declined to ...
Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is ...
H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating on January 21.Invest with ...
Atara Biotherapeutics’ layoffs could leave the biotech with around 80 employees. The cuts follow news that the FDA rejected ...
Atara, Pierre Fabre hit a hurdle with Ebvallo in the US courtesy of manufacturing plant's shortfalls
As partners Atara Biotherapeutics and Pierre Fabre Laboratories work to grow the reach of their novel T-cell immunotherapy ...
LOS ANGELES, CA / ACCESS Newswire / January 29, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/17.DwxO7Jta.js ...
After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...
Atara Biotherapeutics experiences a plunge in share prices after the Food and Drug Administration holds up approval of a drug ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...
Atara Therapeutics’ Ebvallo, already marketed in Europe for a transplant-related blood cancer, will not hit the U.S. market ...
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback